Anixa Biosciences, Inc.

Equities

ANIX

US03528H1095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-24 EDT			5-day change	1st Jan Change
2.5 ^USD	-0.79%		-3.85%	-35.57%

06-24	Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study	MT
06-24	Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial	CI

ITUS Corporation Announces Earnings Results for the Fiscal Year Ending October 31, 2014

January 29, 2015 at 04:53 pm

ITUS Corporation announced earnings results for the fiscal year ending October 31, 2014. For the period, the company reported revenue of $3,667,320, an 840% increase over fiscal 2013, and a 25% reduction in cash used in operating activities to $2,379,261.

Latest news about Anixa Biosciences, Inc.

Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study	06-24	MT
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial	06-24	CI
HC Wainwright Cuts Price Target on Anixa Biosciences to $7 From $12, Maintains Buy Rating	06-10	MT
Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	06-04	CI
Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial	05-21	CI
Anixa Biosciences, Inc. Enters into a Joint Development Agreement with Cleveland Clinic to Develop Novel Vaccines for Various Cancer Types	05-08	CI
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board	04-18	CI
Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-12	CI
Anixa Biosciences Initiates Higher Dosing in Phase 1 Study of Ovarian Cancer Treatment	02-12	MT
Anixa Biosciences Says Japan Grants Patent to Ovarian Cancer Vaccine Technology	01-23	MT
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology	01-23	CI
North American Morning Briefing : Stock Futures Steady as Earnings Season Ramps Up	01-23	DJ
Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-16	CI
North American Morning Briefing : Stock Futures -2-	01-16	DJ
North American Morning Briefing : Samsung Warning Knocks Tech Stocks	01-09	DJ
North American Morning Briefing : Stock Futures Struggle After Weak China Data	01-02	DJ
Anixa Biosciences Unveils 'Positive' Results From Phase 1 Trial of Breast Cancer Vaccine	12-07	MT
Transcript : Anixa Biosciences, Inc. - Special Call	12-06
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine	12-06	CI
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology	11-27	CI
Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board	23-10-23	CI
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial	23-10-13	CI
Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board	23-09-19	CI
Anixa Biosciences, Inc.(NasdaqCM:ANIX) added to S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Concerns About -2-	23-09-07	DJ

Chart Anixa Biosciences, Inc.

Duration

Period

More charts

Company Profile

Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Companyâs vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.5 USD

Average target price

7 USD

Spread / Average Target

+180.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANIXA BIOSCIENCES, INC.	-35.57%	80.02M
MODERNA, INC.	+37.76%	52.5B
IQVIA HOLDINGS INC.	-7.47%	39.01B
LONZA GROUP AG	+37.72%	39.31B
ICON PUBLIC LIMITED COMPANY	+11.93%	26.2B
CELLTRION, INC.	-11.17%	26.57B
ALNYLAM PHARMACEUTICALS, INC.	+16.45%	28.2B
UNITED THERAPEUTICS CORPORATION	+45.05%	14.15B
MEDPACE HOLDINGS, INC.	+33.13%	12.62B
BIO-TECHNE CORPORATION	-3.46%	11.74B

Other Biotechnology & Medical Research